In light of the issues raised in this case, we perhaps will find out the answer to your question if and when she appears to hear the case on the day of argument as a certain 1 of 3, rather than the initial 1 of 12 or more( senior judges) random chance. Others may disagree, but I view the case EPADI-II v. H and R generics to have a relationship to GSK v. TEVA on which she twice appeared in the 2-1 majority.